Cargando…
Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones
Humans and animals are exposed to multiple substances in their food and feed that might have a negative health impact. Among these substances, the Fusarium mycoestrogen zearalenone (ZEN) and its metabolites α-zearalenol (α-ZEL) and α-zearalanol (α-ZAL) are known to possess endocrine disruptive prope...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584851/ https://www.ncbi.nlm.nih.gov/pubmed/35986755 http://dx.doi.org/10.1007/s00204-022-03358-3 |
_version_ | 1784813365564014592 |
---|---|
author | Grgic, Dino Betschler, Andrea Früholz, Rebeka Novak, Barbara Varga, Elisabeth Marko, Doris |
author_facet | Grgic, Dino Betschler, Andrea Früholz, Rebeka Novak, Barbara Varga, Elisabeth Marko, Doris |
author_sort | Grgic, Dino |
collection | PubMed |
description | Humans and animals are exposed to multiple substances in their food and feed that might have a negative health impact. Among these substances, the Fusarium mycoestrogen zearalenone (ZEN) and its metabolites α-zearalenol (α-ZEL) and α-zearalanol (α-ZAL) are known to possess endocrine disruptive properties. In a mixed diet or especially animal feed, these potential contaminants might be ingested together with naturally occurring phytoestrogens such as soy isoflavones. So far, risk assessment of potential endocrine disruptors is usually based on adverse effects of single compounds whereas studies investigating combinatorial effects are scarce. In the present study, we investigated the estrogenic potential of mycoestrogens and the isoflavones genistein (GEN), daidzein (DAI) and glycitein (GLY) as well as equol (EQ), the gut microbial metabolite of DAI, in vitro alone or in combination, using the alkaline phosphatase (ALP) assay in Ishikawa cells. In the case of mycoestrogens, the tested concentration range included 0.001 to 10 nM with multiplication steps of 10 in between, while for the isoflavones 1000 times higher concentrations were investigated. For the individual substances the following order of estrogenicity was obtained: α-ZEL > α-ZAL > ZEN > GEN > EQ > DAI > GLY. Most combinations of isoflavones with mycoestrogens enhanced the estrogenic response in the investigated concentrations. Especially lower concentrations of ZEN, α-ZEL and α-ZAL (0.001—0.01 nM) in combination with low concentrations of GEN, DAI and EQ (0.001—0.1 µM) strongly increased the estrogenic response compared to the single substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-022-03358-3. |
format | Online Article Text |
id | pubmed-9584851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-95848512022-10-22 Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones Grgic, Dino Betschler, Andrea Früholz, Rebeka Novak, Barbara Varga, Elisabeth Marko, Doris Arch Toxicol Biologics Humans and animals are exposed to multiple substances in their food and feed that might have a negative health impact. Among these substances, the Fusarium mycoestrogen zearalenone (ZEN) and its metabolites α-zearalenol (α-ZEL) and α-zearalanol (α-ZAL) are known to possess endocrine disruptive properties. In a mixed diet or especially animal feed, these potential contaminants might be ingested together with naturally occurring phytoestrogens such as soy isoflavones. So far, risk assessment of potential endocrine disruptors is usually based on adverse effects of single compounds whereas studies investigating combinatorial effects are scarce. In the present study, we investigated the estrogenic potential of mycoestrogens and the isoflavones genistein (GEN), daidzein (DAI) and glycitein (GLY) as well as equol (EQ), the gut microbial metabolite of DAI, in vitro alone or in combination, using the alkaline phosphatase (ALP) assay in Ishikawa cells. In the case of mycoestrogens, the tested concentration range included 0.001 to 10 nM with multiplication steps of 10 in between, while for the isoflavones 1000 times higher concentrations were investigated. For the individual substances the following order of estrogenicity was obtained: α-ZEL > α-ZAL > ZEN > GEN > EQ > DAI > GLY. Most combinations of isoflavones with mycoestrogens enhanced the estrogenic response in the investigated concentrations. Especially lower concentrations of ZEN, α-ZEL and α-ZAL (0.001—0.01 nM) in combination with low concentrations of GEN, DAI and EQ (0.001—0.1 µM) strongly increased the estrogenic response compared to the single substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-022-03358-3. Springer Berlin Heidelberg 2022-08-20 2022 /pmc/articles/PMC9584851/ /pubmed/35986755 http://dx.doi.org/10.1007/s00204-022-03358-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Biologics Grgic, Dino Betschler, Andrea Früholz, Rebeka Novak, Barbara Varga, Elisabeth Marko, Doris Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title | Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title_full | Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title_fullStr | Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title_full_unstemmed | Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title_short | Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones |
title_sort | estrogenic in vitro evaluation of zearalenone and its phase i and ii metabolites in combination with soy isoflavones |
topic | Biologics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584851/ https://www.ncbi.nlm.nih.gov/pubmed/35986755 http://dx.doi.org/10.1007/s00204-022-03358-3 |
work_keys_str_mv | AT grgicdino estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones AT betschlerandrea estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones AT fruholzrebeka estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones AT novakbarbara estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones AT vargaelisabeth estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones AT markodoris estrogenicinvitroevaluationofzearalenoneanditsphaseiandiimetabolitesincombinationwithsoyisoflavones |